Positions

Overview

  • Clinton J. Grubbs, Ph.D., is a basic scientist with a primary research interest in the chemoprevention of urinary bladder and mammary cancers. His major area of research is the identification of nutrient and non-nutrient agents that exhibit efficacy in the prevention of these cancers. He is a Professor in the UAB Department of Surgery and a Senior Scientist in the UAB Comprehensive Cancer Center. Dr. Grubbs received his doctoral degree from the University of Tennessee Medical Units in Memphis, Tennessee in 1973. He also completed a two year postdoctoral fellowship in biochemistry at the University of Tennessee Medical Unit. From 1975 to 1979, he was a senior physiologist at the Illinois Institute of Technology in Chicago, Illinois. After six years at Southern Research in Birmingham, he joined the faculty at UAB in the Department of Nutrition Sciences, and in 2000 transferred to the Department of Surgery.

    In 1987, he was awarded Master Agreements from the NCI for in vivo screening of chemopreventive agents and for the evaluation of the efficacy of potential preventive compounds. The agreements, now a Prime Contractor, continue to be active. Through this funding, Dr. Grubbs has established subcontracts for chemoprevention research with five universities and research institutes in the United States. Dr. Grubbs has established a national and international reputation in the preclinical evaluation of chemopreventive agents in cancer. His research is published in widely read peer-reviewed journals. At UAB, he served as Chair of the UAB IACUC Committee from 1987-2001. He also served on the PREVENT Review Panel of the National Cancer Institute for more than 10 years.
  • Principal Investigator On

  • PREVENT Cancer Preclinical and Drug Development Program  awarded by National Cancer Institute/NIH/DHHS 2019 - 2024
  • PREVENT Cancer Preclinical and Drug Development Program  awarded by National Cancer Institute/NIH/DHHS 2019 - 2024
  • TORFP 2019-E03 Evaluation of Two Different Classes of Compounds (STAT3 Inhibitors and SERMs) for Prevention of Urinary Bladder Cancer  awarded by National Cancer Institute/NIH/DHHS 2019 - 2024
  • TORFP 2019-E04 Colorectal Cancer Prevention by Novel EPA Analogue TP-252 and Naproxen in FAP and Lynch Syndrone Models  awarded by National Cancer Institute/NIH/DHHS 2019 - 2024
  • TORFP 2019-E06 Further Development of Colovac, a Multi-Antigen Multi-Peptide Vaccine, for Colon Cancer Prevention  awarded by National Cancer Institute/NIH/DHHS 2019 - 2024
  • Preclinical PREVENT Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers  awarded by National Cancer Institute/NIH/DHHS 2015 - 2021
  • T001 HHSN2610001 Preclinical PREVENT Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers - Kick Off Meeting - Contract Orientation and Kick Off Meeting  awarded by National Cancer Institute/NIH/DHHS 2015 - 2021
  • T002 HHSN2610002 Preclinical PREVENT Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers - Task Order 2015 E-02 - Evaluation of Agents/Protocols that Inhibity the Two Major Pathways Involved in Human Urinary Bladder Cancer [PI3K, EGFR] and Protocols to Reduce their Toxicity  awarded by National Cancer Institute/NIH/DHHS 2015 - 2021
  • T003 HHSN2610003 Preclinical PREVENT Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers - Task Order 2015 E-07 - Evaluation of the Cancer Prevention Efficacy of GLG-302  awarded by National Cancer Institute/NIH/DHHS 2015 - 2021
  • T004 HHSN2610004 Preclinical PREVENT Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers - Immunologic Effects of NSAIDs With and Without a Vaccine in Colon Cancer Prevention  awarded by National Cancer Institute/NIH/DHHS 2015 - 2021
  • T005 HHSN26100005 TORFP 2017-E04 Preclinical PREVENT Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers - Evaluation of "Clinical-Ready" Agents (Bazedoxifene and Lapatinib) in Combination for the Prevention of ER+ and ER- Mammary Cancers  awarded by National Cancer Institute/NIH/DHHS 2015 - 2021
  • T007 HHSN26100007 TORRP-EZ-2018-E01 Evaluation of STAT-3 ANtagonists in the Prevention of Mammary Cancer  awarded by National Cancer Institute/NIH/DHHS 2015 - 2021
  • T008 HHSN26100009 TORFP 2018-E04 Preclinical PREVENT Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers - Evaluating Whether a Concurrent Retinoid X Receptor Agonist Can Enhance the Efficacy of HER2-IGFPB2-IGFLR Vaccine in Eliminating Existing Ductal Carcinoma in Situ and Preventing Progression of Invasive Breast Cancer  awarded by National Cancer Institute/NIH/DHHS 2015 - 2021
  • T009 HHSN26100008 TORFP 2018-E03 Prevention of Urinary Bladder Cancer with Two "Clinically-Ready" Agents (Everolimus and Naproxen) when Administered in Combination  awarded by National Cancer Institute/NIH/DHHS 2015 - 2021
  • T010 HHSN26100010 TORFP 2018-E07 Preclinical Development of a Chemopreventive Agent, 4-Methylumbelliferone (4-MU)  awarded by National Cancer Institute/NIH/DHHS 2015 - 2021
  • T011 HHSN26100011 TORFP 2018-E08 Further Development of Multi-Antigen Vaccines for the Primary and Secondary Prevention of Bladder Cancer  awarded by National Cancer Institute/NIH/DHHS 2015 - 2021
  • Contract Orientation Meeting with NCI, Office of Acquistions  awarded by National Cancer Institute/NIH/DHHS 2014 - 2017
  • HHSN26100002 Efficacacy of a Multi-Antegen Vaccine in the Prevention of MethyInitrosourea-Introduced Mammary Cancers (ER+) in Female Sprague-Dawley Rats  awarded by National Cancer Institute/NIH/DHHS 2014 - 2017
  • HHSN26100003 Chemopreventive Effects in Both Standard Chow Diets and High Fat Diets of Known Positive and Negative Chemopreventative Agents Employing Both High Risk (But Histologically Normally) Mammary Epithelium and Mammary Cancers Including Correlative Biomarkers  awarded by National Cancer Institute/NIH/DHHS 2014 - 2017
  • HHSN26100004 TORFP IV/IV 2013-3 Evaluation of GLG-302, a STAT3 Antagonist in the Prevention of Mammary Cancer  awarded by National Cancer Institute/NIH/DHHS 2014 - 2017
  • HHSN26100005 TORFP IV/IV 2013-4 Efficacy of Metformin in the Methylnitrosourea-Induced Model EF+ Mammary Carcinogenesis when Animals are Placed on Different Diets: Standard Diet, High Fat Diet, and High Fructose Diet  awarded by National Cancer Institute/NIH/DHHS 2014 - 2017
  • HHSN26100006 TORFP 2014-3I Evaluation of the Prevention by Actoplus/Met (Pioglitazone and Metformin) of ER+ and ER- Mammary Cancer Occurring in Rodents on a High-Fat Diet  awarded by National Cancer Institute/NIH/DHHS 2014 - 2017
  • HHSN26100007 TORFP 2014-5I Effect of Bazedoxifene Either Alone or in Combination with an Aromatase Inhibitor or Conjugated Estrogens (CE) in the Prevention of Mammary Cancers  awarded by National Cancer Institute/NIH/DHHS 2014 - 2017
  • Preclinical in Vitro and In Vivo Agent Development Assays  awarded by National Cancer Institute/NIH/DHHS 2014 - 2017
  • Preclinical In Vitro and In Vivo Screening Assays for Cancer Preventive Agent Development  awarded by National Cancer Institute/NIH/DHHS 2004 - 2012
  • Private Grant  awarded by FISHER BIOSERVICES 2009 - 2011
  • OH-BBN Induced Rat Bladder Tumors: Comparative Efficacy of Sulindac, NO-Sulindac and DFMO  awarded by University of Michigan 2008 - 2011
  • Investigator On

  • RXR Rexinoids for Cancer Chemoprevention  awarded by National Cancer Institute/NIH/DHHS 2017 - 2022
  • RXR Rexinoids for Cancer Chemoprevention - Core 3: Rexinoid Screening and Animal Core  awarded by National Cancer Institute/NIH/DHHS 2017 - 2022
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2019 - 2021
  • Comprehensive Cancer Center Core Support Grant - Cancer Chemoprevention Program  awarded by National Cancer Institute/NIH/DHHS 2019 - 2021
  • Preclinical PREVENT Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers  awarded by National Cancer Institute/NIH/DHHS 2015 - 2021
  • Chemoprevention of Breast Cancer with Rexinoids that Inhibit Obesity-Induced Metabolic Syndrome  awarded by National Cancer Institute/NIH/DHHS 2016 - 2019
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2017 - 2019
  • Comprehensive Cancer Center Core Support Grant - Cancer Chemoprevention Program  awarded by National Cancer Institute/NIH/DHHS 2017 - 2019
  • Preclinical in Vitro and In Vivo Agent Development Assays  awarded by National Cancer Institute/NIH/DHHS 2014 - 2017
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2016 - 2017
  • Comprehensive Cancer Center Core Support Grant - Cancer Chemoprevention Program  awarded by National Cancer Institute/NIH/DHHS 2016 - 2017
  • Morehouse School of Medicine/Tuskegee University/University of Alabama Cancer Center Partnership  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Active - Major Program Leader - Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Education And Training

  • Master of Sciences or Mathematics in Biology, University of Tennessee System : Memphis 2000
  • Doctor of Philosophy in Medical Physiology, University of Tennessee System : Memphis 1973
  • Full Name

  • Clinton Grubbs